...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: no web cast - from IR

Well today is the day that "Captain Excited" gets to shine and I won't even be able to watch a broadcast to lighten my day with a chuckle to the forward looking statements.

At least we have Dr Lakhotia in there making progress in building partnerships and science that seems to be progressing, although, I don't think we really are seeing concrete presentations of firm results yet. Perhaps I'm wrong on this.

I see that that the current round of options expire on June 25th, 2026. Don should be close to 70 by then and hopefully long retired. So there may be a chance for some value creation before 2026.

Finally, appointing a weak BOD for the next year is not a sign of hope for the near term.

Desparately hoping I'm wrong.

Toinv

Share
New Message
Please login to post a reply